Harvard Stem Cell Institute (HSCI) researchers have received approval to conduct Somatic Cell Nuclear Transfer (SCNT) experiments aimed at creating disease-specific stem cell lines. This decision follows over two years of rigorous ethical and scientific evaluations. The research is intended to develop treatments for various currently incurable diseases affecting millions. The discussion also highlights challenges in the cloning process, particularly regarding egg harvesting.
PREREQUISITESResearchers, bioethicists, medical professionals, and anyone interested in the advancements and ethical implications of stem cell research and cloning technologies.
I'm for it, go cloning!After more than two years of intensive ethical and scientific review, Harvard Stem Cell Institute (HSCI) researchers at Harvard and Children's Hospital Boston have been cleared to begin experiments using Somatic Cell Nuclear Transfer (SCNT) to create disease-specific stem cell lines in an effort to develop treatments for a wide range of now-incurable conditions afflicting tens of millions of people.